The Transplant Solutions Company •J u n e 5 , 2 0 2 5 Click to edit Master text styles Click to edit Master title style Patrick G, Kidney Transplant Recipient Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including s ...

Key Takeaways QGEN is expanding key platforms with FDA-cleared panels and new digital PCR assay launches. Strategic deals with Eli Lilly, AstraZeneca, and others are fueling QGEN's diagnostic innovations. QGEN maintains solid solvency, with $638.8M in cash and just $56M in current debt as of Q1 2025.QIAGEN N.V. (QGEN) is well-poised to grow in the upcoming quarters, courtesy of substantial investment in research and development (R&D) for the menu expansion of its key platforms. Expanding through partnersh ...